NASDAQ: BMRABiomerica Inc Stock
$2.05-0.04 (-1.91%)
Updated Jun 12, 2026
BMRA Price
$2.05
Fair Value Price
N/A
Market Cap
$6.34M
52 Week Low
$1.87
52 Week High
$4.60
P/E
-1.27x
P/B
1.91x
P/S
1.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.33M
Earnings
-$4.17M
Gross Margin
4.3%
Operating Margin
-96%
Profit Margin
-96.5%
Debt to Equity
0.47
Operating Cash Flow
-$3M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMRA Overview
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BMRA's potential to beat the market
- BMRA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
BMRA
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.51 | A | |
| $37.14 | A | |
| $26.31 | A |
Be the first to know about important BMRA news, forecast changes, insider trades & much more!
BMRA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMRA is good value based on its book value relative to its share price (1.91x), compared to the US Medical Devices industry average (2.98x)
P/B vs Industry Valuation
BMRA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BMRA due diligence checks available for Premium users.
Valuation
BMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.27x
Industry
20.73x
Market
14.15x
BMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
2.98x
BMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMRA's financial health
Profit margin
Revenue
$987.0k
Net Income
-$1.3M
Profit Margin
-132.9%
BMRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BMRA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.9M
Liabilities
$1.6M
Debt to equity
0.47
BMRA's short-term assets ($4.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMRA's short-term assets ($4.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
-$19.0k
Financing
$61.0k
BMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BMRA vs Medical Device Stocks
Biomerica Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.